GUTS - Fractyl Health, Inc Analyst Consensus Forecast

Fractyl Health, Inc. is developing the Revita endoscopic system to combat obesity and diabetes, leveraging FDA approval and implementation across international medical centers. Additionally, the company is creating Rejuvenate gene therapy designed to replace continuous injections, which is attracting interest from major pharma behemoths. The current metric stands at 41.15. The market price action for GUTS securities is presented below.

To seek fundamental stability, it is essential for an investor to evaluate the consensus fair value forecast, calculated as the weighted average of target prices from leading analysts, to determine a safe value range for the asset. The stability of this line neutralizes market noise, which is critical for Fractyl Health, Inc. (GUTS) amid capital-intensive ablation system trials and uncertainty regarding FDA certification timelines.